#United States #National Harbor #ClearStain™ #Pictor Labs #DeepStain™

Pictor Labs Unveils Revolutionary ClearStain™ Technology

In an exciting development for the field of digital pathology, Pictor Labs has announced the launch of its latest innovation, ClearStain™, which promises to transform molecular diagnostic workflows. This breakthrough technology emerges from the company's pioneering work in AI-powered virtual staining and builds on the previous successes of their DeepStain™ and ReStain solutions.

A New Era for Molecular Diagnostics

ClearStain™ represents a significant advancement that allows pathologists to generate AI-powered virtual hematoxylin and eosin (HE) images directly from unstained tissue slides. This capability enables real-time visualization of the precise tissue being tested for molecular diagnostics, facilitating better accuracy and enhanced workflow efficiency. The introduction of ClearStain™ is poised to address common challenges in the diagnostic process, particularly in minimizing the number of sequencing failures experienced in traditional methods.

At a recent showcase at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, held at the Gaylord National Resort & Convention Center in National Harbor, Maryland, Pictor Labs emphasized the importance of this technology in enhancing molecular testing. Attendees had the opportunity to witness firsthand how ClearStain™ demonstrates visual comparability to traditional stained slides in 99-100% of observed areas, a noteworthy achievement in pathology.

The Clear Benefits of ClearStain™

The introduction of ClearStain™ brings several critical advantages to molecular testing:

• - Preservation of Tissue Samples: Unlike conventional chemical staining processes, which can consume or damage tissue samples, ClearStain™ preserves samples for further assays without the risk of loss or contamination.
• - Improved Tumor Purity: By enhancing the quality of the tissue visualization, ClearStain™ improves the purity of tumor samples, which is pivotal for accurate diagnostics.
• - Reduction in Sequencing Failures: By optimizing the workflow, the technology significantly reduces the likelihood of sequencing failures, enabling the rescue of cases that would have previously failed.

Megan Rothney, Vice President of Product at Pictor Labs, highlighted, "With ClearStain™, we empower pathologists to conduct molecular testing with enhanced confidence, directly on the tissue they are analyzing, thus providing crucial data to patients who may not have been able to access it previously."

Addressing the Digital Pathology Market

The healthcare industry is witnessing a rapid transition toward digital pathology, largely driven by the integration of AI-assisted tools. ClearStain™ does not only bridge the gap between histological and molecular data but also seamlessly fits into existing digital pathology workflows. This interoperability is critical as the discrepancy between pathology and precision diagnostics continues to narrow.

Pictor Labs is establishing itself as a key player in the digital sequencing ecosystem, moving beyond just tissue analysis to elevate the standards of molecular diagnostics through its advanced virtual staining technologies.

Looking Ahead with ClearStain™

In conjunction with ClearStain™, Pictor Labs continues to advance its suite of products, which already includes DeepStain™ and ReStain technologies. This integrated approach encapsulates Pictor Labs' mission to enhance research and diagnostics in precision medicine. Rothney reiterated, "Every stain, every pixel, and every decision is informed by data—this is the future of pathology that we are paving the way for with ClearStain™."

For more information about Pictor Labs and its innovative technologies, visit pictorlabs.ai. ClearStain™ not only stands as a technological marvel but also as a beacon of hope for precision medicine, radically redefining diagnostics and improving the quality of patient care.